Park Medi World
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Park Medi World is positioned for robust growth, driven by a disciplined, cluster-based expansion strategy and a focus on high-margin tertiary and quaternary care. Management's optimistic outlook is supported by successful integration of recent acquisitions and a projected revenue CAGR of 24% through FY29. The company's commitment to operational efficiency and a strategic shift in payer mix aims to reduce reliance on government schemes, enhancing profitability. However, risks associated with rapid capacity expansion and maintaining clinical quality during this growth phase remain. Vista's financial outlook reflects stable revenue growth and margins, with a fair valuation aligned with intrinsic value. The healthcare sector's rising demand for organized care and increasing insurance coverage further bolster Park Medi World's growth potential. Over the next 12-24 months, key opportunities include expanding into underpenetrated markets and leveraging technology for clinical outcomes, while watchpoints include managing integration risks and potential margin pressures from new capacity ramp-ups
Why We Like This Stock
- Disciplined cluster-based expansion strategy targeting high-margin services
- Projected revenue CAGR of 24% through FY29, driven by strategic acquisitions
- Strong operational efficiency and a favorable shift in payer mix enhancing profitability
Things To Watch Out For
- Risks associated with rapid capacity expansion and maintaining clinical quality
- Potential margin pressures from new capacity ramp-ups during the integration phase
- High working capital requirements due to reliance on government scheme patients
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,231 | 1,394 | 1,679 | 1,973 | 2,309 |
| Profit Before Tax (Cr.) | 220 | 289 | 355 | 422 | 497 |
| PBT Margin | 17.9% | 20.7% | 21.1% | 21.4% | 21.5% |
| Net Profit (Cr.) | 137 | 208 | 274 | 325 | 361 |
| Earnings Per Share | 3.2 | 4.6 | 6.0 | 7.1 | 8.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 350 | 04-Aug-2026 |
| Emkay Global | ▲ Buy | 350 | 19-Jun-2026 |
Company Overview
Show Company Profile
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.